IL1R

Synonyms

CD121 antigen-like family member A, Interleukin-1 Receptor Type I, Interleukin-1 Receptor Alpha, IL1RA, P80, Interleukin 1 Receptor Alpha, Type I, Interleukin-1 Receptor, Type I, Interleukin 1 Receptor, Type I, CD121a Antigen, D2S1473, Receptors, Interleukin-1, IL-1RT1, IL-1R-alpha, IL1R1, IL1R, IL-1R-1, Interleukin-1 receptor type 1, sIL-1RI, mIL-1RI, IL1RT1, CD121a, sIL-1R1, IL-1RT-1, Interleukin 1 Receptor Type 1, EC:3.2.2.6, mIL-1R1

Description

Interleukin-1 receptor (IL-1R) is a cytokine receptor which binds interleukin 1. After binding to interleukin-1 associates with the coreceptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex. Involved in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells.

KO Status

F1 (+/-)

Drug Information

Launched drugs: 2
Drugs in clinical trials: 9
Latest Research Phase: Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Anakinra biosimilar (AXXO)

Approved

Axxo

Arthritis, Rheumatoid

Anakinra (Amgen/SOBI)

Approved

Amgen Inc

Still's Disease, Adult-Onset, Arthritis, Rheumatoid, Arthritis, Juvenile, Cryopyrin-Associated Periodic Syndromes, Osteoarthritis

Anakinra biosimilar (Shanghai Biomabs)

NDA/BLA

Shanghai Biomabs Pharmaceuticals Co Ltd, Shanghai Cp Guojian Pharmaceutical Co Ltd

Arthritis, Rheumatoid

Hemay-005

Hemay-005

Phase 3 Clinical

Hainan Hailing Chemipharma Corporation Ltd, Tianjin Hemay Pharmaceutical Co Ltd

Spondylitis, Ankylosing, Psoriasis, Arthritis, Psoriatic, Behcet Syndrome, Dermatitis, Atopic, Plaque psoriasis

Anakinra biosimilar (Hamad Medical Corporation)

Phase 3 Clinical

Hamad Medical Corporation

Cytokine Release Syndrome, Pneumonia, Virus Diseases, Coronavirus Disease 2019 (COVID-19), Coronavirus Infections

NK-003

NK-003

Phase 2 Clinical

Pivot Pharmaceuticals

Pancreatitis, Sciatica

Ocular inflammation therapeutic (Tibet Rhodiola Pharmaceutical)

IL-1-Ra

Phase 2 Clinical

Tibet Rhodiola Pharmaceutical Holding Company

Keratitis, Keratoconjunctivitis

Isunakinra

P-05, EBI-005, EBI-005-1, EBI-005-2, 5QM1ZK6VXZ (UNII code)

Phase 2 Clinical

Sesen Bio

Neoplasms, Dry Eye Syndromes, Conjunctivitis, Allergic, Xerophthalmia

Recombinant human interleukin-1 receptor antagonist (General Regeneratives)

GR-007

Phase 2 Clinical

Jiaochen Biological Medicine Technology (Shanghai) Co Ltd

Drug-Related Side Effects and Adverse Reactions, Colorectal Neoplasms

HL-2351

GX-P4, HL-2351, rhIL-1Ra-hyFc

Phase 2 Clinical

Genexine Inc

Arthritis, Rheumatoid, Cryopyrin-Associated Periodic Syndromes

References


Title

Authors

Source

Sequence of the cDNA for the human fibroblast type interleukin-1 receptor

Chua A.O., Gubler U.,

Nucleic Acids Res. 17:10114-10114(1989)

Cloning the interleukin 1 receptor from human T cells

Sims J.E., Acres R.B., Grubin C.E., McMahan C.J., Wignall J.M., March C.J., Dower S.K.,

Proc. Natl. Acad. Sci. U.S.A. 86:8946-8950(1989)

Generation and annotation of the DNA sequences of human chromosomes 2 and 4

Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., Du H., Wilson R.K.,

Nature 434:724-731(2005)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I

Svenson M., Hansen M.B., Heegaard P., Abell K., Bendtzen K.,

Cytokine 5:427-435(1993)

Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses

Giri J.G., Wells J., Dower S.K., McCall C.E., Guzman R.N., Slack J., Bird T.A., Shanebeck K., Grabstein K.H., Sims J.E., Alderson M.R.,

J. Immunol. 153:5802-5809(1994)

Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein

Huang J., Gao X., Li S., Cao Z.,

Proc. Natl. Acad. Sci. U.S.A. 94:12829-12832(1997)

Phosphatidylinositol 3-kinase is recruited to a specific site in the activated IL-1 receptor I

Marmiroli S., Bavelloni A., Faenza I., Sirri A., Ognibene A., Cenni V., Tsukada J., Koyama Y., Ruzzene M., Ferri A., Auron P.E., Toker A., Maraldi N.M.,

FEBS Lett. 438:49-54(1998)

IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells

Tominaga K., Yoshimoto T., Torigoe K., Kurimoto M., Matsui K., Hada T., Okamura H., Nakanishi K.,

Int. Immunol. 12:151-160(2000)

Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways

Slack J.L., Schooley K., Bonnert T.P., Mitcham J.L., Qwarnstrom E.E., Sims J.E., Dower S.K.,

J. Biol. Chem. 275:4670-4678(2000)